Elevated pNF-H levels in CSF and serum are associated with disease severity and progressive MS, supporting their potential as complementary biomarkers of neuroaxonal damage and clinical disability in routine MS assessment.
Abstract
Objective: Axonal injury is a key determinant in irreversible disability in multiple sclerosis (MS). Reliable biomarkers of neuroaxonal damage are essential for improving diagnosis, monitoring disease progression, and evaluating treatment response. This study investigated the relationship between phosphorylated neurofilament heavy chain (pNF-H), clinical characteristics, and conventional cerebrospinal fluid (CSF) and serum biomarkers in Algerian patients with MS. Methods: A total of 102 participants were enrolled. Clinical, immunological, and biochemical parameters were assessed, including the Expanded Disability Status Scale (EDSS), oligoclonal bands (OCBs), IgG index, albumin quotient, and pNF-H concentrations in paired CSF and serum samples. Results: OCBs were detected in 85.5% of patients, and 65.21% exhibited intrathecal immunoglobulin synthesis, with a median IgG index of 0.87. Patients with progressive MS were significantly older and more disabled than those with relapsing–remitting MS (age: p = 0.01; EDSS: p = 0.0007). OCB-positive patients had significantly higher IgG index values (p = 0.0004), but OCB status was not associated with age, EDSS, or albumin quotient. EDSS correlated positively with age (p = 0.0007), albumin quotient (p = 0.01), and IgG index (p = 0.001). Both CSF and serum pNF-H levels were significantly elevated in MS patients compared with NSDs group (p < 0.001). Increased pNF-H concentrations were associated with progressive disease and greater disability (EDSS ≥ 5). Conclusions: Elevated pNF-H levels in CSF and serum are associated with disease severity and progressive MS, supporting their potential as complementary biomarkers of neuroaxonal damage and clinical disability in routine MS assessment.
Introduction: Neurofilament light chains (NfL) are the marker of neuronal injury utilized in many neurological diseases including anti-NMDARE. Nevertheless, the correlation between serum NfL and disease outcome at 2-year follow-up in anti-NMDARE patients remains undetermined.
Objectives/Aims: We aimed to explore the c...
Background: |Cerebrospinal fluid (CSF) contains neuroinflammatory biomarkers, which are molecules measured in central nervous system fluid to track immune activation (neuroinflammation) and glial response. The most significant forms of such markers are STREM tool microgel activity, YKL-40 estradiol activation, and GFAP...
B. J. Asten, A. M. Gelder, I. N. Creemers et al.· Ibn Sina Journal of Medical...· 0 citations
Background: Traumatic spinal cord injury (tSCI) is associated with early neural tissue disruption, systemic inflammation, metabolic stress, and variable neurological outcomes. Although neurological examination and imaging remain central to diagnosis, blood-based biomarkers may provide an additional biochemical window i...
Mustafa Alburhan, Razzaq Sachit, Ameer Aa Aldafaay· Libyan Journal of Applied an...· 0 citations
This study investigated the predictive value of neurofilament light chain (NfL) levels beyond MRI measures of disease activity in multiple sclerosis (MS). This study is a retrospective post hoc analysis of the early interferon treatment group of the combined 5-year REFLEX/REFLEXION studies in clinically isolated syndro...
Rozemarijn M. Mattiesing, G. Gentile, M. Battaglini et al.· Journal of Neurology· 0 citations
Abstract Objectives Serum neurofilament light chain (sNfL) reflects neuroaxonal injury in relapsing-remitting multiple sclerosis (RRMS), but its clinical utility is limited by high interindividual variability and confounders such as renal function. Population-based thresholds may therefore be suboptimal for longitudina...
S. de las Heras Flórez, Gema García de la Rosa, Vicente Martín García et al.· Clinical Chemistry and Labor...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.